Crossmark

A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors

Crossref DOI link: https://doi.org/10.1007/s00262-024-03751-0

Published Online: 2024-07-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vounckx, Manon

Tijtgat, Jens

Stevens, Latoya

Dirven, Iris

Ilsen, Bart

Vandenbroucke, Frederik

Raeymaeckers, Steven

Vekens, Karolien

Forsyth, Ramses

Geeraerts, Xenia

Van Riet, Ivan

Schwarze, Julia Katharina

Tuyaerts, Sandra

Decoster, Lore

De Ridder, Mark

Dufait, Ines

Neyns, Bart
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04571632 at ClinicalTrials.gov

Documents that mention this clinical trial

694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)<sup>+</sup>/CD141(BDCA-3)<sup>+</sup> myeloid dendritic cells in solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.0694

A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors
https://doi.org/10.1007/s00262-024-03751-0
License Information

Text and Data Mining valid from 2024-07-02

Version of Record valid from 2024-07-02
More Information

Article History

Received: 15 March 2024

Accepted: 29 May 2024

First Online: 2 July 2024

Declarations

:

: Conflict of interest: Manon Vounckx: Research funding from Kom op tegen Kanker Jens Tijtgat: Since January 2024 Disease Area Specialist (Medical Lead) Thoracic Oncology at Bristol Myers Squibb Iris Dirven: Research funding: Kom op tegen Kanker; Travel, Accomodations, Expenses: AstraZeneca, Pierre Fabre Julia Katarina Schwarze: JKS reports non-financial support from MSD and Amgen; personal fees from Novartis.Lore Decoster: payments to institution for advisory boards, consultancy, lectures, travel from Astra Zeneca, Roche, MSD, BMS, Servier, Lilly Bart Neyns: Personal financial compensation for public speaking, consultancy, and participation in advisory board meetings from Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis. My institution (UZ Brussel) received research funding related to research projects conducted by my team from Pfizer, Novartis, Roche, and Merck-Serono

Document is current

Any future updates will be listed below